Rahul Shrimanker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rahul Shrimanker has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Ian Douglas Pavord
Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
3 shared publications - Bart Hilvering
Department of Respiratory Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands
2 shared publications - Adaikalavan Ramasamy
University of Oxford
1 shared publication - Ayako Kurioka
University of Oxford
1 shared publication - Catherine Borg
Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, UK
1 shared publication - Christian B. Willberg
Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK
1 shared publication
Latest Publications
- Open Access
Type-2 CD8 + T lymphocytes responsive to PGD 2 and LTE 4 in severe eosinophilic asthma
The functions and in vivo roles of type-2 CD8 + T cells in humans have not been well defined and this cell type has been largely overlooked in models of disease. We investigated this in the context of severe asthma with persistent airway eosinophilia - a phenotype associated with high exacerbation risk and responsiveness to type-2 cytokine-targeted therapies. In two independent cohorts we show that, in contrast to Th2 cells, type-2 cytokine-secreting CD8 + CRTH2 + (Tc2) cells are enriched in blood and airways in severe eosinophilic asthma. Concentrations of prostaglandin D 2 (PGD 2 ) and cysteinyl leukotriene E 4 (LTE 4 ) are also increased in the airways of the same group of patients. In vitro PGD 2 and LTE 4 function synergistically to trigger Tc2 cell recruitment and activation in a TCR-independent manner. These lipids regulate diverse genes in Tc2 cells inducing type-2 cytokines and many other pro-inflammatory cytokines and chemokines which could contribute to eosinophilia. These findings are consistent with an important innate-like role for human Tc2 cells in severe eosinophilic asthma and suggest a potential target for therapeutic intervention in this and other diseases.
Open AccessType-2 CD8 + T lymphocytes responsive to PGD 2 and LTE 4 in severe eosinophilic asthma
The functions and in vivo roles of type-2 CD8 + T cells in humans have not been well defined and this cell type has been largely overlooked in models of disease. We investigated this in the context of severe asthma with persistent airway eosinophilia - a phenotype associated with high exacerbation risk and responsiveness to type-2 cytokine-targeted therapies. In two independent cohorts we show that, in contrast to Th2 cells, type-2 cytokine-secreting CD8 + CRTH2 + (Tc2) cells are enriched in blood and airways in severe eosinophilic asthma. Concentrations of prostaglandin D 2 (PGD 2 ) and cysteinyl leukotriene E 4 (LTE 4 ) are also increased in the airways of the same group of patients. In vitro PGD 2 and LTE 4 function synergistically to trigger Tc2 cell recruitment and activation in a TCR-independent manner. These lipids regulate diverse genes in Tc2 cells inducing type-2 cytokines and many other pro-inflammatory cytokines and chemokines which could contribute to eosinophilia. These findings are consistent with an important innate-like role for human Tc2 cells in severe eosinophilic asthma and suggest a potential target for therapeutic intervention in this and other diseases.
- 1 October 2016
- Published by Fundacio Barcelona Respiratory Network in Barcelona Respiratory Network
- Vol. 2 (4)
Practising Personalized Medicine in Asthma
- 1 October 2016
- Published by Fundacio Barcelona Respiratory Network in Barcelona Respiratory Network
- Vol. 2 (4)
Practising Personalized Medicine in Asthma
- 1 August 2016
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 36 (3) , 609-623
Emerging Biologics in Severe Asthma
- 1 August 2016
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 36 (3) , 609-623
Emerging Biologics in Severe Asthma